New York, NY | January 05, 2023 – As legal cannabis continues to enjoy broad, bipartisan support among the general public and as more states legalize the substance for either medical or recreational purposes, a recently released landmark study sheds new light on the conditions for which patients seek medical cannabis and how those conditions vary by geographic region, age, and gender identity.

The study, the 2022 Cannabis Conditions Report, was conducted by NuggMD using more than 210,000 anonymized patient records, among the largest data sets of its kind. NuggMD is a telemedicine provider that helps patients obtain medical cannabis cards in 22 states. It conducted the study in order to add more facts to the prevailing dialogue about the addition of medical cannabis to a treatment regimen.

The full report is available here. It was first reported by Marijuana Moment, one of the nation’s leading trackers of developments and news in the cannabis industry.

Concurrent with its Conditions Report, NuggMD also released the details of a complementary survey of more than 500 current medical cannabis card-holders. Importantly, 68 percent of respondents said they have ceased or reduced other pharmaceutical treatments since incorporating medical cannabis. More than 80 percent of respondents said they are comfortable discussing medical cannabis with their doctors, and more than 94 percent said cannabis provides to them moderate or total relief of the conditions for which they sought treatment.

“The evidence here is clear: medical cannabis works. It provides relief for a wide variety of conditions. More importantly, it’s giving patients an alternative to dangerously addictive, often deadly pharmaceuticals. More than a century of disinformation and propaganda peddled by cannabis foes does not change these facts,” said Alex Milligan, co-founder and chief marketing officer of NuggMD.

Analysis: Inconsistent standards limit access and create unreliable data

Still, a significant barrier to access is how states limit the qualifying conditions for which a patient may be recommended medical cannabis. In some states, legislators have expanded their regulations to include more qualifying conditions or to allow physicians to recommend medical cannabis in broad terms, such as for treatment of a “debilitating medical condition.” Other states continue to unjustly prohibit their residents from accessing this form of healthcare.

Of note, the states that allow physicians to determine the qualifying condition saw a higher rate of patients reporting “other condition” as a reason they were seeking medical cannabis. Based on that datapoint, NuggMD believes that states with fewer qualifying conditions are either deterring patients from seeking the medication they need or reducing the accuracy of available data by forcing patients in need of medical cannabis to select a comorbidity rather than the primary ailment for which they were seeking an evaluation. A majority of patients in the study listed multiple conditions, which can be expected as many conditions exist co-morbidly.

“From a policy standpoint, one piece of low-hanging fruit for lawmakers is more consistency to the qualifying conditions under which states approve medical cannabis licenses for patients,” said Milligan. “The current status quo does not promote equal access to care or the evidence-based evaluation of medical outcomes, which are both cornerstones of other areas of healthcare.”

The report was authored by NuggMD’s Alexandra Arnett, a University of Maryland School of Pharmacy candidate for a Master of Science in Medical Cannabis Science and Therapeutics. Medical review was provided by Dr. Brian Kessler, MD, Pain Management & Sports Medicine, with analysis, editing, and fact-checking conducted by NuggMD’s Tyler Elson and Deb Tharp.

About NuggMD

NuggMD is the nation’s leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They’ve connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com.

Contact Details

Andrew Graham

[email protected]

Company Website

http://www.nuggmd.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vermont ketamine treatment facility added to fast-growing chain of psychedelic mental-health clinics

LOS ANGELES, Aug. 15, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of its first Vermont clinic, continuing what has been the rapid expansion of this nationally known brand name into the emerging field of psychedelic mental healthcare.

Irwin Naturals Emergence previously acquired five ketamine clinics in Florida, one in Iowa., one in New Hampshire, and two in Georgia. This acquisition fulfills the agreement, which was first announced on June 17, to add the clinic in Colchester, Vermont, to the national chain of Irwin Naturals Emergence.

Klee Irwin, CEO of Irwin Naturals, said, “We’re at the very, very beginning of the rapid expansion of psychedelic mental-health clinics in this country. We’re moving fast right now to take advantage of this opportunity to be the first national brand in this space, establishing ourselves as the first name people will think of when it comes to receiving these life-changing treatments.”

Dr. Hobie Fuerstman, physician and owner of Preventive Medicine, said, “Our goal of providing quality, holistic care to our community will be amplified by this move in several ways, creating opportunities to expand the range of patients we can reach while also driving down the cost, thereby improving access.”

The clinic practices neuromuscular medicine and integrative health in addition to offering ketamine infusion treatments. Fuerstman took ownership of the clinic in 2020 when he moved to Vermont. A founding member of the Psychedelic Society of Vermont, he has advocated the need to use ketamine-assisted therapy to treat disorders like depression and anxiety.

Today’s acquisition is the latest step in what has been an aggressive national rollup for Irwin Naturals Emergence. For the past several months, the company has vetted the more than 600 independent ketamine clinics currently operating in the United States, seeking to identify clinics that are profitable while also demonstrating a high-standard of patient care. The company has sought to acquire those clinics that meet the criteria, quickly making Irwin Naturals Emergence a national presence.

There is an economic advantage to becoming part of a bigger chain as economies of scale and the adoption of company-wide best practices can drive down operating costs. The eventual savings will be passed on to customers by providing sliding-scale discounts and even pro bono treatment for those in need.

The power of the Irwin Naturals brand provides something that may be even more important: leverage. The name itself brings a level of not just familiarity but loyalty in this emerging field of care. Irwin Naturals has been in business since 1994, providing best-in-class nutraceuticals and earning customer trust and popular recognition that have made it a brand name recognized in 80 percent of U.S. households.¹ Irwin Naturals products are stocked on the shelves of more than 100,000 storefronts in North America, and now that brand is moving to the forefront of this new frontier of healthcare.

Klee Irwin, Irwin Naturals CEO, “We’re sending customers a message simply by being in this space. Our products have safely treated your health needs for 28 years. We’re proof that psychedelic mental-health treatment is legitimate and safe and will provide the healing that you need.”

Transaction terms

As consideration for the acquisition, Irwin Naturals will provide sellers cash payments as well as 284,848 subordinate voting shares upon closing. Furthermore, the transaction includes an additional contingent consideration based on future milestones related to operational and profitability targets, to be satisfied in shares.

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class herbal supplement formulator since 1994. It is now leveraging its brand to enter into both the cannabis and psychedelic industries. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years.² Irwin’s growing portfolio of products is available in more than 100,000 retail doors across North America, where nearly 100 million people know the Irwin Naturals brand.³ In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products nationwide. The Company is now leveraging its famous halo of brand trust with an objective to become one of the first household name brands to offer THC-based products and psychedelic mental health treatment. Irwin Naturals became a publicly traded company on the Canadian Securities Exchange (CSE) in August 2021. The Company’s shares began to be traded on the OTCQB Venture Market in November 2021. More information on the Company’s stock can be found via Bloomberg as well as the Wall Street Journal.

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
[email protected]

IR Information

For investor-related information, please visit ir.irwinnaturals.com/, call (800) 883-4851, or email [email protected].

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
[email protected]

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, “objective,” or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Forward-looking statements in this news release include statements related to information concerning the ability of the Company to perform the terms of the transaction referenced herein; the receipt of all necessary approvals, including regulatory approvals; expectations for other economic, market, business and competitive factors; and the Company actually entering into and doing business in the U.S. cannabis and psychedelics markets The potential entrance by the Company into these new business segments are in their preliminary stages and may be subject to approval from the board of directors of the Company as well as any regulatory approval, including that of the Canadian Securities Exchange. These statements are based on numerous assumptions that are believed by management to be reasonable in the circumstances, and are subject to a number of risks and uncertainties, including without limitation: board and regulatory approval, including the approval of the Canadian Securities Exchange; Irwin being able to acquire and/or enter into business relationships to enter into these new markets; the Company obtaining the required licenses; and changes to regulations and laws regarding cannabis or psychedelics. Further information on the regulatory environment and risks will be contained in future disclosures. Forward-looking statements are subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from that which are expressed or implied by such forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

¹ Based on a formal Company survey with a sample size of 500 randomly selected adults.
² Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.
³ Consumer brand recognition information is based on a formal Company survey with a sample size of 500 randomly selected adults.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.